<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zarifyan, Alla</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Williams, Bryan</style></author><author><style face="normal" font="default" size="100%">Brown, Morris J.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">PATHWAY-2 and -3</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2015-10-21 10:14:30</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">12-13</style></pages><abstract><style  face="normal" font="default" size="100%">PATHWAY-2 and PATHWAY-3 demonstrated that potassium-sparing diuretics are safe and effective for the treatment of hypertension. Spironolactone was significantly more effective in controlling resistant hypertension than doxazosin or bisoprolol, whereas the amiloride/HCTZ combination neutralized the undesirable changes in blood glucose and potassium while significantly lowering blood pressure.</style></abstract><number><style face="normal" font="default" size="100%">28</style></number><volume><style face="normal" font="default" size="100%">15</style></volume></record></records></xml>